LeMaitre Vascular Stock Tumbles on Q2 Earnings Miss, Lowered Full-Year Outlook

Shares of LeMaitre Vascular (LMAT) fell more than 16% in pre-open trading Wednesday after the company released a disappointing second-quarter 2026 earnings report and lowered its forward guidance, citing multiple headwinds.

Earnings and Guidance Fall Short

The Burlington, Massachusetts-based company reported quarterly results late Tuesday that missed Wall Street expectations on both revenue and profit. Compounding the miss, LeMaitre issued a weaker-than-expected outlook for the upcoming quarter and the full year.

• Q2 2026 EPS: $0.74, below the analyst consensus of $0.81.
• Q2 2026 Revenue: $70.4 million, missing the anticipated $71.47 million.
• Q3 2026 Guidance: The company projects EPS of $0.66–$0.71 and revenue of $66.3–$68.3 million, both below consensus estimates of $0.73 and $69.0 million, respectively.
• Full-Year 2026 Outlook: LeMaitre trimmed its full-year organic revenue growth target to 11% from a prior forecast of 12% and lowered its EPS outlook to a range of $2.84–$2.94.

Headwinds Overshadow Operational Strengths

Ad

Management attributed the reduced forecast to several challenges, including foreign exchange pressures, supply constraints, and delays related to the situation in the Middle East. The negative outlook overshadowed some positive operational results from the second quarter.

Despite the misses, the company reported 10% organic sales growth, a 26% increase in operating income, and a record operating margin of 29%. Sales of its Artegraft product, a key growth driver, were up 34% and accounted for 21% of total revenue.

Market Reaction

The sharp, company-specific sell-off stood in stark contrast to the broader market, where futures for major U.S. indices were trading higher. The combination of a rare earnings miss, a weak Q3 forecast, and a reduced full-year target prompted investors to re-evaluate the stock's near-term growth prospects, pushing the pre-market price closer to its 52-week low.